Equities analysts expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to post earnings per share (EPS) of ($0.64) for the current quarter, according to Zacks. Zero analysts have provided estimates for Zynerba Pharmaceuticals’ earnings, with estimates ranging from ($0.66) to ($0.61). Zynerba Pharmaceuticals reported earnings per share of ($0.71) in the same quarter last year, which suggests a positive year over year growth rate of 9.9%. The company is scheduled to issue its next earnings report on Monday, March 26th.

According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full year earnings of ($2.49) per share for the current year, with EPS estimates ranging from ($2.54) to ($2.45). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.34) per share, with EPS estimates ranging from ($2.64) to ($2.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.05). During the same period in the previous year, the business earned ($0.67) EPS.

ZYNE has been the subject of a number of research reports. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Thursday, October 12th. ValuEngine raised shares of Zynerba Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Piper Jaffray Companies lifted their price objective on shares of Zynerba Pharmaceuticals from $16.00 to $20.00 in a report on Tuesday, November 14th. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, November 14th. Finally, Cantor Fitzgerald set a $17.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $15.00.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) opened at $11.40 on Tuesday. Zynerba Pharmaceuticals has a 1-year low of $5.42 and a 1-year high of $25.95.

In other news, major shareholder Michael Rapp purchased 44,255 shares of Zynerba Pharmaceuticals stock in a transaction dated Thursday, October 19th. The stock was bought at an average price of $9.59 per share, with a total value of $424,405.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.91% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors acquired a new stake in Zynerba Pharmaceuticals in the second quarter worth about $110,000. The Manufacturers Life Insurance Company acquired a new stake in Zynerba Pharmaceuticals in the second quarter worth about $158,000. New York State Common Retirement Fund acquired a new stake in Zynerba Pharmaceuticals in the second quarter worth about $207,000. Parametric Portfolio Associates LLC acquired a new stake in Zynerba Pharmaceuticals in the second quarter worth about $223,000. Finally, Zeke Capital Advisors LLC acquired a new stake in Zynerba Pharmaceuticals in the third quarter worth about $114,000. 26.95% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/12/zynerba-pharmaceuticals-inc-zyne-expected-to-announce-earnings-of-0-64-per-share.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.